Cadila gets US OK for cholesterol lowering pravastatin
MUMBAI, May 7 (Reuters) - The U.S. Food and Drug Administration has approved Cadila Healthcare Ltd's (CADI.BO: Quote, Profile, Research) cholesterol-fighter pravastatin sodium tablets in various strengths, the regulator's Web site showed on Wednesday.
The U.S. agency also tentatively approved the Indian drug maker's losartan potassium-hydrochlorothiazide tablets used to lower high blood pressure. (Reporting by Bharghavi Nagaraju; Editing by Ramya Venugopal)
© Thomson Reuters 2009 All rights reserved
Pledge to support economies
G20 financial leaders pledged to prepare strategies to end emergency support for their economies, but to keep the aid flowing until recovery was assured. Full Article | Related Story
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article





India
US
UK










